Clinical trials: Neuroectodermal Tumors, Primitive
Ewing Sarcoma Family of Tumors
Assessment of MGMT Promoter Methylation in Advanced Ewing Sarcoma Treated With Temozolomide and Irinotecan
This is a biological study in patients with advanced Ewing Sarcoma who received, according, clinical practice, temozolomide and irinotecan The O6-methylguanine-DNA methyltransferase (MGMT) methylation status, will be correlated…
- Trial name
- MGMTLiberati (NCT03542097)
- Testing
- MGMT methylation evaluation
- Where
- 5 sites in Italy, United Kingdom
- Volunteers
- 82 people
- Sponsor
- Istituto Ortopedico Rizzoli
Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Background: Cancers of the nasal cavity or skull base are rare. They often are not diagnosed until they are at an advanced stage, and they often spread to other parts of the body.
- Conditions
- Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma, Metastatic Sinonasal Adenocarcinoma, Locally Advanced Sinonasal Adenocarcinoma
- Trial name
- NCT06176989
- Testing
- Enasidenib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
RATIONALE: Vaccines may help the body build an effective immune response to kill cytomegalovirus infections. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who have…
- Trial name
- NCT00509691
- Testing
- cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Louisville
Brain Neoplasms, Glioma
A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors
The presence of a highly selective blood-brain barrier (BBB) at the level of the brain capillary endothelium prevents chemotherapeutic agents from attaining therapeutic concentrations at the target site.
- Conditions
- Brain Neoplasms, Glioma, Medulloblastoma
- Trial name
- NCT00001502
- Testing
- RMP-7 and carboplatin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
NB2013-HR German (GPOH) / Dutch (DCOG) Trial
Although the five year survival rate of children with high risk neuroblastoma have increased over the last three decades from 4 to 44 % (1), neuroblastoma is the second most frequent cause for cancer related death in childhood…
- Trial name
- NB2013-HR (NCT02641782)
- Testing
- antibody ch14.18, GM-CSF, IL-2 i.v.
- Where
- Germany
- Volunteers
- 3 people
- Sponsor
- University of Cologne
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of oblimersen in treating patients who have solid tumors…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00003103
- Testing
- oblimersen sodium, docetaxel
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer, Mucositis Oral
GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer
GM-CSF may protect normal cells from the side effects, such as mucositis, of radiation therapy and may help damaged tissue heal faster after radiation therapy.
- Conditions
- Head and Neck Cancer, Mucositis Oral, Radiation Toxicity, Tongue Cancer
- Trial name
- NCT00293462
- Testing
- sargramostim, oral salt and soda mouthwash
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Marilyn Dodd
Recurrent Neuroblastoma
Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma
Phase I trial to compare the effectiveness of interleukin-12 with or without interleukin-2 in treating young patients who have refractory or recurrent neuroblastoma.
- Trial name
- NCT00054405
- Testing
- recombinant interleukin-12, aldesleukin
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colon Cancer
Genomic Structural Variation in Cancer Susceptibility
This study will look for new types of gene changes that may be related to cancer in some patients. Some gene changes (mutations) are passed on from parents to offspring (child).
- Conditions
- Breast Cancer, Colon Cancer, Germ Cell Cancer, Neuroblastoma
- Trial name
- NCT00996710
- Where
- United States
- Volunteers
- 1,275 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pediatric Central Nervous System Tumors, Medulloblastoma
Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors
his is a single-center, prospective observational study in children and adolescents with central nervous system tumors who need whole-brain and whole-spine radiation therapy (craniospinal irradiation, CSI).
- Conditions
- Pediatric Central Nervous System Tumors, Medulloblastoma, Germinoma, Ependymoma
- Trial name
- VBS-CSI-PT-PED (NCT07589361)
- Testing
- Vertebral Body-Sparing Craniospinal Proton Irradiation
- Volunteers
- 38 people
- Sponsor
- Ruijin Hospital
Kidney Cancer, Leukemia
Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors
RATIONALE: Glutamine may help lessen neuropathy caused by chemotherapy. It is not yet known whether glutamine is more effective than a placebo in treating neuropathy caused by vincristine.
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Neurotoxicity
- Trial name
- NCT00365768
- Testing
- Glutamine
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Columbia University
Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the…
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma
- Trial name
- NCT04320888
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- 174 sites in United States, Australia and 1 more
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
Biomarkers in Young Patients With Neuroblastoma
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01169376
- Testing
- DNA analysis, DNA methylation analysis, RNA analysis
- Volunteers
- 380 people
- Sponsor
- Children's Oncology Group
Transplant-Associated Thrombotic Microangiopathy, Neuroblastoma
Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma
This phase II trial tests how well defibrotide works in preventing transplant-associated thrombotic microangiopathy (TA-TMA) in patients with high-risk neuroblastoma undergoing tandem transplants (hematopoietic stem cell…
- Conditions
- Transplant-Associated Thrombotic Microangiopathy, Neuroblastoma, High-risk Neuroblastoma, Thrombotic Microangiopathies
- Trial name
- NCT06182410
- Testing
- Defibrotide
- Sponsor
- University of California, San Francisco
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
This is a Phase I/II, multicenter, open-label, multi-arm study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of idasanutlin, administered as a single agent or in combination with…
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Solid Tumors
- Trial name
- NCT04029688
- Testing
- Idasanutlin, Venetoclax, Cyclophosphamide
- Where
- 14 sites in United States, Canada and 4 more
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Neuroblastoma
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
This is a multi-center, single arm trial of two doses of 18 mCi/kg of Ultratrace iobenguane I 131 administered to subjects with high-risk neuroblastoma.
- Trial name
- NCT00992173
- Testing
- Ultratrace Iobenguane I 131
- Where
- 21 sites in United States, Canada
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Medulloblastoma
Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma
Medulloblastoma is a rare brain malignancy, mainly affecting children. Treatment of this rapidly growing tumor begins with maximal surgical removal plus radiation and chemotherapy. Treatment toxicity is high.
- Trial name
- PersoMed-I (NCT04402073)
- Testing
- Sonidegib, Cisplatin, Lomustine
- Where
- 50 sites in Australia, Austria and 6 more
- Volunteers
- 20 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Neuroblastoma, GD2 Antibody
A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma
This is a prospective, single-arm, open, single-center clinical trial to evaluate the safety and efficacy of autologous NK cells combined with chemotherapy and GD2 monoclonal antibody in the treatment of newly diagnosed high-risk…
- Conditions
- Neuroblastoma, GD2 Antibody, Autologous NK Cell
- Trial name
- NCT06948994
- Testing
- autologous NK cell plus GD2 antibody
- Volunteers
- 15 people
- Sponsor
- Guangzhou Women and Children's Medical Center
Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Ewing Sarcoma of Bone
18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma
This pilot trial studies fluorine F 18 fluorothymidine (18F-FLT) positron emission tomography and diffusion-weighted magnetic resonance imaging in planing surgery and radiation therapy and measuring response in patients with…
- Conditions
- Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT01825902
- Testing
- fluorine F 18 fluorothymidine, fludeoxyglucose F 18, positron emission tomography
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs)
Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China
The goal of this observational study is to validate the EQ-5D-Y-3L and EQ-5D-Y-5L in measuring health-related quality of life (HRQoL) for paediatric patients with different health conditions in China.
- Conditions
- Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs), Pneumonia Childhood, Neuroblastoma (NB)
- Trial name
- NCT06873672
- Where
- China
- Volunteers
- 360 people
- Sponsor
- RenJi Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.